Please select the option that best describes you:
Do you offer adjuvant chemoimmunotherapy after IFRT for Stage I to II low grade follicular lymphoma?
TROG 99.03 showed nearly 20% improved PFS at 10 years with chemoimmunotherapy despite 31/75 patients assigned R-CVP vs 44/75 assigned CVP without rituximab. If you do offer treatment, what factors into your decision?
Answer from: Medical Oncologist at Academic Institution
I do not. Absent overall survival benefit, which is not seen or reported, this strategy overtreats the subset of patients who are cured with RT alone, and prematurely exposes the other group to the toxicity of chemotherapy.
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The most recent data that utilize rituximab-containing systemic therapy (CVP) after definitive IFRT come from MacManus et al. (Randomized Trial of Systemic Therapy After IFRT in Patients with Early-Stage Follicular Lymphoma: TROG 99.03. JCO. 2018 36:29, 2918-2925). Ten-year PFS rates ...